Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDVRG.L Regulatory News (DVRG)

  • There is currently no data for DVRG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Microtox Successful Phase 3 Field Trials

24 Jun 2021 07:00

RNS Number : 9129C
Deepverge PLC
24 June 2021
 

 

 

24 June 2021

 

DeepVerge plc

 

("DeepVerge" or the "Company")

 

Microtox® PD claims world first live data alerts of SARS-Cov-2 in wastewater treatment plants

 

Modern Water enters Service Agreement with EPS Group for European Microtox®PD[i] installations

 

DeepVerge (LSE:DVRG.L), today announces the successful completion of Phase 3 field trials in which Microtox® PD achieved real-time detection and transmission of data, specific to SARS-CoV-2, in wastewater treatment plants at multiple sites[ii]. As a result, its Environmental Health Division ("Modern Water") has entered into a master service agreement with EPS Group to install, calibrate, service and maintain Microtox®PD units which, subject to negotiation with undisclosed parties, have the potential to be installed in multiple European countries.

 

Gerard Brandon, DeepVerge plc CEO commented:

"The successful completion of the Phase 3 field trials clearly demonstrates the capability and value of Microtox® PD to identify dangerous pathogens, including SARS-CoV-2, in real-time. By establishing a permanent anonymised mass surveillance of wastewater, DeepVerge claims a world first real-time defence against this global pandemic. The installation of Microtox® PD wastewater units will enable live data to simultaneously identify the source of COVID-19 cases as well as identify COVID-19 clusters with the ability to indicate the size of each cluster. As the data grows, the central AI system has the potential to predict the trajectory of growth of future clusters of SARS-CoV-2 or any future dangerous pathogen.

 

"Having achieved this major milestone, we are delighted to enter this agreement with EPS Group who complete the final step of installing, retrofitting and maintaining our Microtox® PD equipment. With this level of established technical engineering support and distribution, DeepVerge can now offer an end-to-end solution for public and private clients across the European wastewater sector. We expect updates from our Joint Venture agreement with China Resources and roll-out in the US to follow early in Q3."

 

Patrick Buckley, EPS Group Managing Director commented:

"We are very pleased to be part of this innovative partnership with DeepVerge to help combat the pandemic with their unique Microtox® PD technology playing a crucial role in the early detection of COVID-19 hotspots around the world. With 550 personnel, our largest footprint in the water, wastewater pumping and treatment services sector across Europe, EPS Group engineers are ready to make this happen".

 

Background to field trials:

On the 24 September 2020, the Company announced[iii] completion of the integration of an Affimer/Aptamer-based real-time SARS-CoV-2 detector and alert system into Modern Water's Microtox water contamination system, now called Microtox® PD , for the detection of the coronavirus in wastewater. Microtox® PD successfully completed initial spike protein testing and validation of SARS-CoV-2 in filtered wastewater and transitioned to the University of Aberdeen for full beta testing of the system using real SARS-CoV-2 virus samples in its containment level 3 laboratory, prior to initiation of the field trials, referred to above. 

 

Contacts

 

DeepVerge plc

Gerard Brandon, CEO

+44 (0) 7340 055 648

SPARK Advisory Partners Limited

(Nominated Adviser)

Neil Baldwin/Andrew Emmott

+44 (0) 113 370 8974

Turner Pope Investments (TPI) Limited (Broker)

Andy Thacker/James Pope

+44 (0) 20 3657 0050

 

 

About DeepVerge plc (www.deepverge.com)

DeepVerge is an environmental and life science group of companies that develops and applies AI and IoT technology to analytical instruments for the analysis and identification of bacteria, virus and toxins. Utilising artificial intelligent data analytics to scientifically prove the impact of skincare product claims on skin microbiome for most of the top 20 global cosmetic company clients and remotely detect and identify in real-time, dangerous pathogens in wastewater treatment plants, drinking water, rivers, lakes and reservoirs.

 

About EPS Group (www.epswater.ie)

EPS Group is one of largest, privately owned Design-Build-Operate European partners for the delivery, operation and concession management of water and wastewater assets. A wet infrastructure specialist, employing approximately 550 people with revenues in excess of £100m. With a 52 year pedigree, EPS has grown from a modest electrical and pumping services business into an innovative, internationally exporting product and service provider, focused on water, wastewater and clean technology.

 

EPS Group work across the utility; industrial; commercial; residential and agricultural sectors with customers as varied as water and power companies; those in the dairy, meat processing, bakery, brewing and distilling industries; pharmaceuticals, biotechnology, microelectronic, data centre and defence spaces to commercial including building services, leisure, office/retail outlets and SMEs to residential and agricultural clients.

 


[i] Microtox® PD has been designed to be retrofitted into existing Modern Water equipment to detect and identify a range of infectious viruses and bacteria including SARS-CoV-2, E.coli, Legionella and Cryptosporidium, on a single chip, using AI, in real-time.

 

[ii] First deployments of Microtox® PD Microtox® PD

 https://irpages2.equitystory.com/websites/rns_news/English/1100/news-tool---rns---eqs-group.html?iframe=true&article=31443290&company=Deepverge&iframe=true

 

[iii] COVID-19 wastewater Microtox ready for beta testing https://irpages2.equitystory.com/websites/rns_news/English/1100/news-tool---rns---eqs-group.html?iframe=true&article=31216869&company=Deepverge&iframe=true

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCSEDFWDEFSEFM
Date   Source Headline
27th Dec 20237:00 amRNSCancellation - DEEPVERGE PLC
20th Dec 202312:30 pmRNSUpdate; exclusivity agreement with Microsaic
13th Dec 20234:38 pmRNSUpdate
14th Sep 20237:00 amRNSNew Website, Update
7th Aug 20232:30 pmRNSDisposal;Update; Related Party Trans'n-replacement
7th Aug 20237:00 amRNSDisposal; Update
2nd Aug 20239:35 amRNSBoard Change
1st Aug 20237:00 amRNSCompany Secretary Change
12th Jul 20237:00 amRNSUpdate
5th Jul 202311:26 amRNSUpdate
26th Jun 20237:30 amRNSSuspension - Deepverge PLC
26th Jun 20237:00 amRNSSale or closure of subsidiaries; share suspension
5th Jun 20237:00 amRNSCost reductions;delay to Ann. Report;New contract
19th Apr 20231:21 pmRNSMicrosaic Creditor; Update
17th Apr 20237:00 amRNS2022 revenue update - revision
24th Mar 202310:24 amRNSChange of Auditor
6th Mar 20234:35 pmRNSPrice Monitoring Extension
6th Mar 20232:05 pmRNSSecond Price Monitoring Extn
6th Mar 20232:00 pmRNSPrice Monitoring Extension
22nd Feb 20234:40 pmRNSSecond Price Monitoring Extn
22nd Feb 20234:35 pmRNSPrice Monitoring Extension
7th Feb 20237:00 amRNSBoard Appointment
6th Feb 20235:30 pmRNSSignificant contract win and Board change
2nd Feb 20234:40 pmRNSSecond Price Monitoring Extn
2nd Feb 20234:35 pmRNSPrice Monitoring Extension
9th Jan 20237:00 amRNS2022 Revenue Update
23rd Nov 20224:10 pmRNSTR-1: Notification of major holdings
22nd Nov 20227:00 amRNSAccelerated Restructuring
16th Nov 20229:00 amRNSDirector/PDMR Shareholding
14th Nov 202212:16 pmRNSResult of Meeting
11th Nov 20224:37 pmRNSHolding(s) in Company
7th Nov 20227:00 amRNSDirectorate and Management Changes
3rd Nov 202212:32 pmRNSDirectorate Change
1st Nov 20223:56 pmRNSResult of Broker Offer; Total Voting Rights
31st Oct 20222:23 pmRNSBroker Offer to raise a max of £2.5m - replacement
31st Oct 20222:18 pmRNSExtension of Broker Offer to 430pm on 31 October
28th Oct 20221:06 pmRNSExtension of Broker Offer
27th Oct 20227:01 amRNSBroker Offer to raise a maximum of £2.5m
27th Oct 20227:00 amRNS£10m Placing, Broker Option, RPTs, Notice of GM
25th Oct 20222:05 pmRNSSecond Price Monitoring Extn
25th Oct 20222:00 pmRNSPrice Monitoring Extension
25th Oct 20227:01 amRNSUpdate - Proposed Financing,Proposed Board Changes
25th Oct 20227:00 amRNSHistorical Related Party Transactions
12th Oct 20224:41 pmRNSSecond Price Monitoring Extn
12th Oct 20224:35 pmRNSPrice Monitoring Extension
12th Oct 20227:04 amRNSResponse to Market Speculation
11th Oct 202211:05 amRNSSecond Price Monitoring Extn
11th Oct 202211:00 amRNSPrice Monitoring Extension
4th Oct 20227:00 amRNSLabskin contract
30th Sep 20224:41 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.